Xeris Biopharma (XERS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.31, +2.38% vs the prior close of $10.07.
- Volume 2.29M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
XERS rises 2.4% to $10.31. Closed at $10.31, +2.38% vs the prior close of $10.07. Day range $9.85–$10.33, opened at $10.04.
XERS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — XERS rises 2.4% to $10.31
- Closed at $10.31, +2.38% vs the prior close of $10.07. Day range $9.85–$10.33, opened at $10.04.
- Volume was 2.29M shares, 0.9x its 50-day average of 2.43M.
- Price is +16.3% vs its 50-day average ($8.86) and +40.4% vs its 200-day average ($7.34).
- 52-week range $5.25–$11.33; today's close sits at 83% of that range, 9.0% below the 52-week high.
Oct 15, 2026 — XERS jumps 3.1% to $10.07
- Closed at $10.07, +3.07% vs the prior close of $9.77. Day range $9.76–$10.18, opened at $9.77.
- Volume was 1.94M shares, 0.8x its 50-day average of 2.43M.
- Price is +14.4% vs its 50-day average ($8.81) and +37.4% vs its 200-day average ($7.33).
- 52-week range $5.25–$11.33; today's close sits at 79% of that range, 11.1% below the 52-week high.
Oct 14, 2026 — XERS slides 4.2% to $9.77, 3 down days in a row
- Closed at $9.77, -4.22% vs the prior close of $10.20. Day range $9.73–$10.39, opened at $10.08.
- Volume was 2.37M shares, 1.0x its 50-day average of 2.42M.
- Price is +11.4% vs its 50-day average ($8.77) and +33.5% vs its 200-day average ($7.32).
- 52-week range $5.25–$11.33; today's close sits at 74% of that range, 13.8% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — XERS dips 2.5% to $10.20
- Closed at $10.20, -2.49% vs the prior close of $10.46. Day range $10.15–$10.50, opened at $10.41.
- Volume was 2.22M shares, 0.9x its 50-day average of 2.41M.
- Price is +16.8% vs its 50-day average ($8.73) and +39.6% vs its 200-day average ($7.30).
- 52-week range $5.25–$11.33; today's close sits at 81% of that range, 10.0% below the 52-week high.
Oct 12, 2026 — XERS ends flat (-0.2%) to $10.46
- Closed at $10.46, -0.19% vs the prior close of $10.48. Day range $10.33–$10.55, opened at $10.47.
- Volume was 1.33M shares, 0.5x its 50-day average of 2.42M — lighter than usual.
- Price is +20.3% vs its 50-day average ($8.69) and +43.5% vs its 200-day average ($7.29).
- 52-week range $5.25–$11.33; today's close sits at 86% of that range, 7.7% below the 52-week high.
Oct 9, 2026 — XERS rises 2.8% to $10.48, a 52-week high, 3 up days in a row
- Closed at $10.48, +2.85% vs the prior close of $10.19. Day range $10.07–$10.60, opened at $10.15.
- Volume was 3.00M shares, 1.3x its 50-day average of 2.37M.
- Price is +21.2% vs its 50-day average ($8.65) and +44.1% vs its 200-day average ($7.27).
- 52-week range $5.25–$11.33; today's close sits at 86% of that range, 7.5% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — XERS rises 0.8% to $10.19, a 52-week high
- Closed at $10.19, +0.79% vs the prior close of $10.11. Day range $10.00–$10.35, opened at $10.10.
- Volume was 1.98M shares, 0.8x its 50-day average of 2.36M.
- Price is +18.4% vs its 50-day average ($8.60) and +40.4% vs its 200-day average ($7.26).
- 52-week range $5.25–$11.33; today's close sits at 81% of that range, 10.1% below the 52-week high.
Oct 7, 2026 — XERS rises 0.4% to $10.11
- Closed at $10.11, +0.40% vs the prior close of $10.07. Day range $9.91–$10.27, opened at $10.00.
- Volume was 2.22M shares, 1.0x its 50-day average of 2.33M.
- Price is +18.0% vs its 50-day average ($8.57) and +39.6% vs its 200-day average ($7.24).
- 52-week range $5.25–$11.33; today's close sits at 80% of that range, 10.8% below the 52-week high.
Oct 6, 2026 — XERS dips 0.6% to $10.07
- Closed at $10.07, -0.59% vs the prior close of $10.13. Day range $9.90–$10.33, opened at $10.23.
- Volume was 2.40M shares, 1.0x its 50-day average of 2.30M.
- Price is +18.0% vs its 50-day average ($8.53) and +39.3% vs its 200-day average ($7.23).
- 52-week range $5.25–$11.33; today's close sits at 79% of that range, 11.1% below the 52-week high.
Oct 5, 2026 — XERS jumps 11.6% to $10.13, a 52-week high on 2.1x normal volume
- Closed at $10.13, +11.56% vs the prior close of $9.08. Day range $9.12–$10.24, opened at $9.15.
- Volume was 4.66M shares, 2.1x its 50-day average of 2.23M — unusually heavy trading.
- Price is +19.3% vs its 50-day average ($8.49) and +40.5% vs its 200-day average ($7.21).
- 52-week range $5.25–$11.33; today's close sits at 80% of that range, 10.6% below the 52-week high.
Oct 2, 2026 — XERS dips 1.8% to $9.08, 3 down days in a row
- Closed at $9.08, -1.84% vs the prior close of $9.25. Day range $9.04–$9.34, opened at $9.34.
- Volume was 1.80M shares, 0.8x its 50-day average of 2.24M.
- Price is +7.4% vs its 50-day average ($8.46) and +26.2% vs its 200-day average ($7.20).
- 52-week range $5.25–$11.33; today's close sits at 63% of that range, 19.9% below the 52-week high.
- That makes 3 straight losses.
XERS latest news & SEC filings
Every SEC filing by or about XERS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pieper Steven sold 5,000 shares at $9.41 (≈$47.04K) on Oct 1, 2026; now holds 1,351,053
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mcculloch Kevin sold 15,000 shares at $9.41 (≈$141.12K) on Oct 1, 2026; now holds 1,599,208
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hecht Beth sold 16,666 shares at $9.41 (≈$156.79K) on Oct 1, 2026; now holds 1,111,130
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mcculloch Kevin sold 25,000 shares at $10.00 (≈$250.00K) on Sep 28, 2026; now holds 1,614,208
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $92.10M (prior year $71.54M) (+28.7% vs Jun 30, 2025)
- Net income: -$31.10M (prior year -$1.93M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.18 (prior year -$0.01) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Jun 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade XERS
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 2, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.07% (largest 11.6%). That is a volatile stock.
- Liquidity: about 3.36M shares (≈$34.64M) trade per day on average.
- 52-week position: $10.31 vs a range of $5.25–$11.33 (83% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Kevin Mcculloch sold 25,000 shares on Sep 28, 2026.
- Latest filings: 8-K Oct 14, 2026; 8-K Sep 9, 2026; 10-Q Aug 6, 2026.
- Share count: 182.32M shares outstanding (Jul 31, 2026), +12.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
XERS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.04 | 10.33 | 9.85 | 10.31 | 2.29M |
| Oct 15, 2026 | 9.77 | 10.18 | 9.76 | 10.07 | 1.94M |
| Oct 14, 2026 | 10.08 | 10.39 | 9.73 | 9.77 | 2.37M |
| Oct 13, 2026 | 10.41 | 10.50 | 10.15 | 10.20 | 2.22M |
| Oct 12, 2026 | 10.47 | 10.55 | 10.33 | 10.46 | 1.33M |
| Oct 9, 2026 | 10.15 | 10.60 | 10.07 | 10.48 | 3.00M |
| Oct 8, 2026 | 10.10 | 10.35 | 10.00 | 10.19 | 1.98M |
| Oct 7, 2026 | 10.00 | 10.27 | 9.91 | 10.11 | 2.22M |
| Oct 6, 2026 | 10.23 | 10.33 | 9.90 | 10.07 | 2.40M |
| Oct 5, 2026 | 9.15 | 10.24 | 9.12 | 10.13 | 4.66M |
| Oct 2, 2026 | 9.34 | 9.34 | 9.04 | 9.08 | 1.80M |
| Oct 1, 2026 | 9.52 | 9.69 | 9.18 | 9.25 | 3.59M |
| Sep 30, 2026 | 9.97 | 10.07 | 9.55 | 9.56 | 3.75M |
| Sep 29, 2026 | 9.77 | 11.33 | 9.50 | 9.98 | 19.31M |
| Sep 28, 2026 | 9.05 | 10.01 | 9.00 | 9.83 | 4.46M |
| Sep 25, 2026 | 8.99 | 9.15 | 8.85 | 9.10 | 1.55M |
| Sep 24, 2026 | 8.65 | 9.00 | 8.56 | 8.95 | 1.36M |
| Sep 23, 2026 | 8.74 | 9.20 | 8.46 | 8.66 | 2.04M |
| Sep 22, 2026 | 8.90 | 8.97 | 8.64 | 8.73 | 1.69M |
| Sep 21, 2026 | 8.28 | 8.81 | 8.16 | 8.80 | 3.23M |
About Xeris Biopharma
Xeris Biopharma (XERS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CHICAGO, IL. Fiscal year ends December 31. SEC CIK 1867096.
XERS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Barbara-Jean Anne Bormann-Kennedy | Director | Jun 5, 2026 |
| James Aloysius Brady | Director | Jun 5, 2026 |
| Dawn Halkuff | Director | Jun 5, 2026 |
| John Johnson | Director | Jun 5, 2026 |
| Nerissa Kreher | Director | Jul 2, 2026 |
| Garheng Kong | Director | Jun 5, 2026 |
| Marla Persky | Director | Jun 5, 2026 |
| John Patrick Jr Shannon | See Remarks | Aug 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Beth Hecht | See Remarks | Sep 1, 2026 |
| Kevin Mcculloch | See Remarks | Sep 29, 2026 |
| Anh Tu Nguyen | See Remarks | Feb 25, 2026 |
| Steven Pieper | See Remarks | Sep 1, 2026 |
| John Patrick Jr Shannon | See Remarks | Aug 21, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 28, 2026 | Kevin Mcculloch | Sale | 25,000 | $10.00 |
| Sep 28, 2026 | Kevin Mcculloch | Sale | 25,000 | $10.00 |
| Sep 28, 2026 | Kevin Mcculloch | Sale | 25,000 | $10.00 |
| Sep 28, 2026 | Kevin Mcculloch | Sale | 25,000 | $10.00 |
| Sep 1, 2026 | Steven Pieper | Sale | 5,000 | $8.50 |
| Sep 1, 2026 | Steven Pieper | Sale | 5,000 | $8.50 |
| Sep 1, 2026 | Steven Pieper | Sale | 5,000 | $8.50 |
| Sep 1, 2026 | Steven Pieper | Sale | 5,000 | $8.50 |
| Sep 1, 2026 | Beth Hecht | Sale | 16,666 | $8.49 |
| Sep 1, 2026 | Beth Hecht | Sale | 16,666 | $8.49 |
| Sep 1, 2026 | Beth Hecht | Sale | 16,666 | $8.49 |
| Sep 1, 2026 | Beth Hecht | Sale | 16,666 | $8.49 |
| Sep 1, 2026 | Kevin Mcculloch | Sale | 15,000 | $8.49 |
| Sep 1, 2026 | Kevin Mcculloch | Sale | 15,000 | $8.49 |
| Sep 1, 2026 | Kevin Mcculloch | Sale | 15,000 | $8.49 |
XERS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $291.85M | $554.00K | 0.00 | $28.63M |
| Dec 31, 2024 | $203.07M | $-54.84M | -0.37 | $-36.98M |
| Dec 31, 2023 | $163.91M | $-62.26M | -0.45 | $-47.02M |
| Dec 31, 2022 | $110.25M | $-94.66M | -0.70 | $-102.89M |
| Dec 31, 2021 | $49.59M | $-122.72M | -1.55 | $-95.53M |
Latest balance sheet: total assets $411.90M, total liabilities $421.64M, cash $121.75M (as of Jun 30, 2026).
XERS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $7.36 |
| May 7, 2026 | 8-K Item 2.02 (results) | $6.63 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $6.02 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $8.13 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $7.71 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $6.60 |
| May 8, 2025 | 8-K Item 2.02 (results) | $5.16 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $4.13 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $3.40 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $3.47 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| Jul 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on XERS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.